In summary, these data demonstrate that the adenosine A2A receptor agonist CGS21680 suppresses NETosis triggered by APS patient antibodies, and that PKA is a downstream effector of this suppression. This evidence concerns the gene ADORA2A and autoimmune polyendocrinopathy.